MCID: ART008
MIFTS: 42

Arteriosclerosis Obliterans malady

Category: Cardiovascular diseases

Aliases & Classifications for Arteriosclerosis Obliterans

About this section

Aliases & Descriptions for Arteriosclerosis Obliterans:

Name: Arteriosclerosis Obliterans 11 49 38 13 67

Classifications:



External Ids:

Disease Ontology11 DOID:5160
SNOMED-CT61 361133006, 60625000
MeSH38 D001162

Summaries for Arteriosclerosis Obliterans

About this section
Wikipedia:70 Arteriosclerosis obliterans is an occlusive arterial disease most prominently affecting the abdominal... more...

MalaCards based summary: Arteriosclerosis Obliterans is related to coronary artery disease and ischemic heart disease. An important gene associated with Arteriosclerosis Obliterans is SELP (Selectin P), and among its related pathways are LDL Oxidation in Atherogenesis and Thromboxane A2 receptor signaling. The drugs tolazoline and tolazoline hydrochloride have been mentioned in the context of this disorder. Affiliated tissues include heart, bone and bone marrow, and related mouse phenotypes are cardiovascular system and cellular.

Related Diseases for Arteriosclerosis Obliterans

About this section

Diseases related to Arteriosclerosis Obliterans via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 88)
idRelated DiseaseScoreTop Affiliating Genes
1coronary artery disease29.8ADIPOQ, IL6, SELP
2ischemic heart disease29.5HTR2A, IL6, SELP
3myocardial infarction29.5ADIPOQ, ICAM1, IL6, SELP
4peripheral artery disease29.1ADIPOQ, ICAM1, IL6, SELP, VCAM1
5arteriosclerosis10.9
6histoplasmosis10.4IL6, SELP
7antidepressant type abuse10.4ADIPOQ, IL6
8colon carcinoma in situ10.4IL6, SELP
9vibrio vulnificus infection10.3ICAM1, IL6
10orbital lymphangioma10.3IL6, VCAM1
11overnutrition10.3ICAM1, VCAM1
12lymphomatoid papulosis10.3ICAM1, VCAM1
13rhizomelic pseudopolyarthritis10.3ICAM1, VCAM1
14saethre-chotzen syndrome10.3HGF, IL6
15sarcoidosis, early-onset10.3HGF, IL6
16cutaneous leishmaniasis10.3HGF, IL6
17hereditary renal cell carcinoma10.3ICAM1, IL6
18spastic paraplegia 3a10.3SELP, VCAM1
19posterolateral myocardial infarction10.3ICAM1, VCAM1
20kaposi sarcoma10.3HGF, IL6
21corpus callosum dysgenesis cleft spasm10.3ADIPOQ, VCAM1
22acute dacryocystitis10.3ICAM1, VCAM1
23autoimmune polyendocrine syndrome10.3HGF, IL6
24substernal goiter10.3HGF, IL6
25liver disease10.2ICAM1, VCAM1
26speech disorder10.2ICAM1, IL6
27chromophobe adenoma10.2ICAM1, VCAM1
28dentin dysplasia10.2ICAM1, VCAM1
29conjunctival disease10.2ICAM1, IL6
30uveitis10.2ICAM1, VCAM1
31alopecia10.2ICAM1, IL6
32hordeolum externum10.2ADIPOQ, VCAM1
33aneurysm10.1
34angina pectoris10.1IL6, SELP, VCAM1
35heart disease10.1
36atypical follicular adenoma10.1ICAM1, IL6, SELP
37developmental coordination disorder10.1ICAM1, ITGA4
38intracranial primitive neuroectodermal tumor10.1ICAM1, SELP, VCAM1
39phagocyte bactericidal dysfunction10.1ICAM1, IL6, SELP
40thymus lymphoma10.1HGF, IL6
41ischemia10.1
42aortic aneurysm10.1
43west nile fever10.0ICAM1, IL6, VCAM1
44dementia - subcortical10.0ICAM1, IL6, VCAM1
45focal epilepsy10.0IL6, SELP
46hodgkin's lymphoma, mixed cellularity10.0ICAM1, IL6, VCAM1
47renal fibrosis10.0HGF, IL6
48conventional malignant hemangiopericytoma10.0ICAM1, IL6
49artery disease10.0
50extrahepatic cholestasis9.9HGF, IL6

Graphical network of the top 20 diseases related to Arteriosclerosis Obliterans:



Diseases related to arteriosclerosis obliterans

Symptoms for Arteriosclerosis Obliterans

About this section

Drugs & Therapeutics for Arteriosclerosis Obliterans

About this section

Drugs for Arteriosclerosis Obliterans (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 57)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Sevofluraneapproved, vet_approvedPhase 447928523-86-65206
Synonyms:
1,1,1,3,3,3-Hexafluoro-2-(fluoromethoxy)propane
28523-86-6
AC-15484
AC1L1JU0
BRN 2041023
Bax 3084
C009250
C07520
C4H3F7O
CHEBI:9130
CHEMBL1200694
CID5206
D00547
DB01236
F0691
Fluoromethyl 1,1,1,3,3,3-Hexafluoroisopropyl Ether
Fluoromethyl 2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether
I14-13357
LS-67851
MR6S4
 
MR_6S4
MolPort-001-775-746
NCGC00167421-01
PC4681
Sevofluran
Sevoflurane
Sevoflurane (JAN/USAN/INN)
Sevoflurane [USAN:INN:BAN:JAN]
Sevoflurano
Sevoflurano [INN-Spanish]
Sevofluranum
Sevofluranum [INN-Latin]
Sevofrane
Sevorane
Sojourn
UNII-38LVP0K73A
Ultane
Ultane (TN)
ZINC01530810
fluoromethyl hexafluoroisopropyl ether
fluoromethyl-2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether
sevoflurane
2
Propofolapproved, investigational, vet_approvedPhase 410282078-54-84943
Synonyms:
2, 6-Diisopropylphenol
2,6 Diisopropylphenol
2,6-Bis(1-methylethyl)phenol
2,6-Bis(Isopropyl)-phenol
2,6-DIISOPROPYLPHENOL
2,6-Diisopropyl phenol
2,6-Diisopropylphenol
2,6-bis(1-methylethyl)-phenol
2,6-di(propan-2-yl)phenol
2078-54-8
28449-97-0
4-06-00-03435 (Beilstein Handbook Reference)
50356-15-5
AB00513968
AC-2038
AC1L1J9Y
AC1Q1OUI
AI3-26295
AM-149
Abbott Brand of Propofol
Alpha Brand of Propofol
Ampofol
Aquafol
Astra Brand of Propofol
AstraZeneca Brand of Propofol
BIDD:GT0436
BPBio1_000950
BPBio1_000969
BRD-K82255054-001-03-5
BRN 1866484
BSPBio_000862
Biomol-NT_000248
Braun Brand of Propofol
C07523
C12H18O
CAS-2078-54-8
CCRIS 9000
CHEBI:44915
CHEMBL526
CID4943
CPD-11437
CPD000059151
Curamed Brand of Propofol
D00549
D015742
D0617
D126608
D126608_ALDRICH
DB00818
DDS-04F
Diisopropylphenol
Dipravan
Diprivan
Diprivan (TN)
Diprivan Injectable emulsion
Disoprivan
Disoprofol
EINECS 218-206-6
EU-0100437
Fresenius Brand of Propofol
Fresenius Kabi Brand of Propofol
Fresofol
HMS1570L04
HMS2089O21
HMS2094E17
 
HSDB 7123
ICI 35,868
ICI 35868
ICI-35,868
ICI-35868
ICI35,868
ICI35868
InChI=1/C12H18O/c1-8(2)10-6-5-7-11(9(3)4)12(10)13/h5-9,13H,1-4H
Ivofol
Jsp004266
Juste Brand of Propofol
LS-996
Lopac-D126608
Lopac0_000437
MLS001066348
MLS001335999
MLS002454360
MolPort-001-794-517
NCGC00015389-01
NCGC00015389-02
NCGC00015389-04
NCGC00015389-09
NCGC00091538-01
NCGC00091538-02
NCGC00091538-03
NCGC00091538-04
NCGC00091538-05
NCGC00091538-06
NSC 5105
NSC5105
PFL
Parnell Brand of Propofol
Pisa Brand of Propofol
Prestwick0_000931
Prestwick1_000931
Prestwick2_000931
Prestwick3_000931
Propofol
Propofol (JAN/USAN/INN)
Propofol Abbott
Propofol Fresenius
Propofol IDD-D
Propofol MCT
Propofol Rovi
Propofol [USAN:INN:BAN]
Propofol(2,6-Diisopropylphenol)
Propofol-Lipuro
Propofolum
Propofolum [Latin]
Rapinovet
Recofol
Rovi Brand of Propofol
S01-0189
SAM002264610
SMR000059151
SPBio_003031
SPECTRUM1505022
ST50405911
Schering Brand of Propofol
UNII-YI7VU623SF
W505102_ALDRICH
ZD-0859
ZINC00968303
Zeneca Brand of Propofol
ghl.PD_Mitscher_leg0.558
nchembio.552-comp7
propofol
3
RemifentanilapprovedPhase 4446132875-61-760815
Synonyms:
1-Piperidinepropanoic acid, 4-(methoxy-carbonyl)-4-((1-oxopropyl)phenylamino)-, methyl ester
132539-07-2 (mono-hydrochloride)
132875-61-7
3-(4-methoxycarbonyl-4-((1-oxopropyl)phenylamino)-1-piperidine)propanoic acid methyl ester
4-carboxy-4-(n-phenylpropionamido)-1-piperidinepropionic acid dimethyl ester
AC1L1TZ8
AC1Q5ZGR
BIDD:GT0029
C08021
CHEBI:8802
CHEMBL1005
CID60815
D08473
DB00899
 
DEA No. 9739
GI 87084B
GI 87084X
GI87084B
L001266
LS-115982
MolPort-004-286-006
REMIFENTANIL
Remifentanil (INN)
Remifentanil [INN:BAN]
Remifentanyl
UNII-P10582JYYK
Ultiva
Ultiva (TN)
methyl 1-(3-methoxy-3-oxopropyl)-4-(N-propanoylanilino)piperidine-4-carboxylate
4
CilostazolapprovedPhase 410373963-72-12754
Synonyms:
3,4-Dihydro-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-2(1H)-quinolinone
3,4-dihydro-6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-2(1H)-quinolinone
6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-2(1H)-quinolinone
6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydrocarbostyril
6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxyl)-3,4-dihydrocarobostyril
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-1H-quinolin-2-one
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone
6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydroquinolin-2(1H)-one
6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one
73963-72-1
89332-50-3
AC-4334
AC1L1EE2
BRD-K67017579-001-04-2
BRD-K67017579-001-05-9
BRD-K67017579-001-07-5
BRD-K67017579-001-13-3
BRN 3632107
BSPBio_002759
C 0737
C045645
C0737_SIGMA
C20H27N5O2
CHEBI:31401
CHEMBL799
CID2754
CL23867
CPD000058428
Cilostazol (JP15/USAN/INN)
Cilostazol [INN:JAN]
Cilostazole
Cilostazolum
Cilostazolum [INN-Latin]
D01896
DB01166
EU-0100218
HMS1922N15
HMS2093M14
KBio3_002259
KBioGR_001184
 
LS-142693
Lopac-C-0737
Lopac0_000218
MLS000028470
MLS000758281
MLS000759507
MLS001076067
MLS002153891
MolPort-001-758-007
NCGC00015207-01
NCGC00015207-02
NCGC00015207-06
NCGC00015207-10
NCGC00022153-02
NCGC00022153-04
NCGC00022153-05
NCGC00022153-06
NCGC00022153-07
OPC 13013
OPC 21
OPC-13013
OPC-21
Otsuka brand of cilostazol
Pletaal
Pletal
Pletal (TN)
Pletal, Cilostazol
S1294_Selleck
SAM001246734
SAM001247085
SMR000058428
SPBio_001256
SPECTRUM1505230
Spectrum2_001118
Spectrum3_001170
Spectrum4_000772
Spectrum5_001762
TL8005113
Tocris-1692
UNII-N7Z035406B
ZINC01552174
cilostazol
5
Aspirinapproved, vet_approvedPhase 4111250-78-22244
Synonyms:
11126-35-5
11126-37-7
1oxr
2-(ACETYLOXY)benzoic acid
2-(Acetyloxy)benzoate
2-(Acetyloxy)benzoic acid
2-Acetoxybenzenecarboxylic acid
2-Acetoxybenzoate
2-Acetoxybenzoic acid
2-Carboxyphenyl acetate
2349-94-2
26914-13-6
50-78-2
8-hour Bayer
98201-60-6
A 5376
A.S.A
A.S.A.
A.S.A. Empirin
A.S.A. empirin
A2093_SIGMA
A3160_SIGMA
A5376_SIGMA
A6810_SIGMA
AB1003266
AC 5230
AC1L1D8U
AC1Q1LA0
ACETYLSALICYLIC ACID
AI3-02956
AIN
AKOS000118884
ASA
Acenterine
Acesal
Acetal
Acetard
Aceticyl
Acetilsalicilico
Acetilum acidulatum
Acetisal
Acetol
Acetonyl
Acetophen
Acetosal
Acetosalic acid
Acetosalin
Acetoxybenzoic acid
Acetylin
Acetylsal
Acetylsalicylate
Acetylsalicylic acid
Acetylsalicylsaeure
Acetylsalicylsaure
Acetylsalycilic acid
Acetyonyl
Acetysal
Acetysalicylic acid
Acide 2-(acetyloxy)benzoique
Acide acetylsalicylique
Acide acétylsalicylique
Acido O-acetil-benzoico
Acido acetilsalicilico
Acidum acetylsalicylicum
Acimetten
Acisal
Acylpyrin
Adiro
Aloxiprimum
Asacard
Asagran
Asatard
Ascoden-30
Aspalon
Aspec
Aspergum
Aspir-Mox
Aspirdrops
Aspirin
Aspirin (JP15/USP)
Aspirin [BAN:JAN]
Aspirina 03
Aspirine
Asprin
Aspro
Aspro Clear
Asteric
Azetylsalizylsaeure
Azetylsalizylsäure
BIDD:GT0118
BRN 0779271
Bay-e-4465
Bayer
Bayer Aspirin 8 Hour
Bayer Buffered
Bayer Extra Strength Aspirin For Migraine Pain
Bayer Plus
Benaspir
Bi-prin
Bialpirina
Bialpirinia
Bufferin
C01405
CCRIS 3243
CHEBI:15365
CHEMBL25
CID2244
Caprin
Cardioaspirin
Cardioaspirina
Cemirit
Claradin
Clariprin
Colfarit
Contrheuma retard
Coricidin
Crystar
D00109
D001241
DB00945
Decaten
Delgesic
Dispril
DivK1c_000555
Dolean pH 8
Duramax
ECM
EINECS 200-064-1
EU-0100038
Easprin
Easprin (TN)
Ecolen
Ecotrin
Empirin
Empirin with Codeine
Endosprin
Endydol
 
Entericin
Enterophen
Enterosarein
Enterosarine
Entrophen
Extren
Globentyl
Globoid
HMS1920E13
HMS2090G03
HMS2091K13
HMS501L17
HSDB 652
Helicon
I14-7505
IDI1_000555
Idragin
Istopirin
KBio1_000555
KBio2_001725
KBio2_002271
KBio2_004293
KBio2_004839
KBio2_006861
KBio2_007407
KBio3_002149
KBio3_002751
KBioGR_000398
KBioGR_002271
KBioSS_001725
KBioSS_002272
Kapsazal
Kyselina 2-acetoxybenzoova
Kyselina acetylsalicylova
LS-143
Levius
Lopac-A-5376
Lopac0_000038
MLS001055329
MLS001066332
MLS001336045
MLS001336046
Magnecyl
Measurin
Medisyl
Micristin
MolPort-000-871-622
NCGC00015067-01
NCGC00015067-04
NCGC00015067-09
NCGC00090977-01
NCGC00090977-02
NCGC00090977-03
NCGC00090977-04
NCGC00090977-05
NCGC00090977-06
NCGC00090977-07
NCI60_002222
NINDS_000555
NSC 27223
NSC27223
NSC406186
Neuronika
Novid
Nu-seals
Nu-seals aspirin
O-(Acetyloxy)benzoate
O-(Acetyloxy)benzoic acid
O-Acetoxybenzoate
O-Acetoxybenzoic acid
O-Acetylsalicylic acid
O-Carboxyphenyl acetate
O-accetylsalicylic acid
O-acetylsalicylic acid
PL-2200
Persistin
Pharmacin
Pirseal
Polopirin
Polopiryna
Premaspin
R16CO5Y76E [UNII]
Rheumin tabletten
Rheumintabletten
Rhodine
Rhonal
Ronal
S-211
SMR000059138
SP 189
SPBio_001838
SPECTRUM1500130
ST075414
Salacetin
Salcetogen
Saletin
Salicylic acid acetate
Salicylic acid, acetate
Salospir
Solfrin
Solprin
Solprin acid
Solpyron
Solupsan
Spectrum2_001899
Spectrum3_001295
Spectrum4_000099
Spectrum5_000740
Spectrum_001245
Spira-Dine
St. Joseph
St. Joseph Aspirin for Adults
Supac
Tasprin
Temperal
Toldex
Triaminicin
Triple-sal
UNII R16CO5Y76E
UNII-R16CO5Y76E
UNII=R16CO5Y76E
UNM-0000306102
Vanquish
WLN: QVR BOV1
XAXA
Xaxa
Yasta
ZORprin
aspirin
cMAP_000006
component of Midol
component of Synirin
nchem.859-comp6
o-Acetoxybenzoic acid
o-Carboxyphenyl acetate
o-acetoxybenzoic acid
o-carboxyphenyl acetate
ácido acetilsalicílico
6
ProbucolapprovedPhase 42123288-49-54912
Synonyms:
2,6-ditert-butyl-4-[2-(3,5-ditert-butyl-4-hydroxyphenyl)sulfanylpropan-2-ylsulfanyl]phenol
23288-49-5
4,4'- (Isopropylidenedithio)bis(2, 6-di-tert-butylphenol)
4,4'- (Isopropylidenedithio)bis(2,6-di-tert-butylphenol)
4,4'-(Isopropylidenedithio)bis(2, 6-di-tert-butylphenol)
4,4'-(Isopropylidenedithio)bis(2,6-di-tert-butylphenol)
4,4'-(Isopropylidenedithio)bis[2, 6-di-tert-butylphenol]
4,4'-(Isopropylidenedithio)bis[2,6-di-tert-butylphenol]
4,4'-(propane-2,2-diyldisulfanediyl)bis(2,6-di-tert-butylphenol)
4,4'-[(1-Methylethylidene)bis(thio)]bis-[2,6-bis(1,1-dimethylethyl)phenol]
AB00052202
AC1L1J88
AKOS001740866
Acetone bis(3,5-di-tert-butyl-4-hydroxyphenyl) mercaptole
Acetone, bis (3,5-di-tert-butyl-4-hydroxyphenyl) mercaptole
Acetone, bis(3,5-di-tert-butyl-4-hydroxyphenyl) mercaptole
Almirall Brand of Probucol
Aventis Brand of Probucol
BPBio1_000625
BRN 2026253
BSPBio_000567
BSPBio_003176
Biphenabid
Bisbid
Bisphenabid
C07373
C31H48O2S2
CAS-23288-49-5
CCRIS 7510
CHEBI:122641
CHEMBL608
CID4912
D00476
D011341
DB01599
DE-3872
DH 581
DH-581
DH581
DivK1c_000599
EINECS 245-560-9
HMS1569M09
HMS1921D21
HMS2092D05
HMS501N21
Hoechst Brand of Probucol
IDI1_000599
KBio1_000599
KBio2_001776
KBio2_002394
KBio2_004344
KBio2_004962
KBio2_006912
KBio2_007530
 
KBio3_002396
KBio3_002873
KBioGR_000708
KBioGR_002394
KBioSS_001776
KBioSS_002399
LORELCO (TN)
LS-13188
Lesterol
Lorelco
Lursell
Lurselle
MLS000028492
MolPort-002-042-265
NCGC00016777-01
NCGC00094895-01
NCGC00094895-02
NCGC00094895-03
NCGC00094895-04
NINDS_000599
NSC 652160
NSC 86225
NSC652160
NSC86225
P9672_FLUKA
P9672_SIGMA
Panavir
Prestwick0_000384
Prestwick1_000384
Prestwick2_000384
Prestwick3_000384
Prestwick_408
Probucol (JAN/USP/INN)
Probucol [USAN:BAN:INN:JAN]
Probucolum
Probucolum [INN-Latin]
Probucolum [inn-latin]
SMR000058265
SPBio_001420
SPBio_002488
SPECTRUM1501109
ST075698
STK762566
Serterol
Sinlestal
Spectrum2_001400
Spectrum3_001438
Spectrum4_000414
Spectrum5_001343
Spectrum_001296
Superlipid
UNII-P3CTH044XJ
ZERO/001429
ZINC01530755
cMAP_000039
probucol
7
Valsartanapproved, investigationalPhase 4291137862-53-460846
Synonyms:
(2S)-3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid
(S)-N-Valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine
(S)-N-valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine
(s)-2-(n-((2'-(1h-tetrazol-5-yl)biphenyl-4-yl)methyl)pentanamido)-3-methylbutanoic acid
137862-53-4
AC-4543
AC1L1U1M
AC1Q5QIK
Ambap137862-53-4
Aventis brand of valsartan
BIDD:GT0345
BRD-K45158365-001-02-3
BSPBio_003501
Bio-0796
C081489
C24H29N5O3
CEPA brand of valsartan
CGP 48933
CGP-48933
CHEBI:9927
CHEMBL1069
CID60846
CPD000466318
D00400
DB00177
Diovan
Diovan (TN)
Diovan, Valsartan
Esteve brand of valsartan
HMS1922L21
HMS2051L12
HMS2093K22
HSDB 7519
KBio2_002287
KBio2_004855
KBio2_007423
KBio3_003006
KBioGR_001078
KBioSS_002289
 
Kalpress
L-Valine, N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI)
LS-161334
Lacer brand of valsartan
MLS000759423
MLS001424088
Miten
MolPort-002-507-854
MolPort-003-666-608
N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine
N-(P-(O-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine
N-(p-(o-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine
N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-L-valine
N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valine
N-valeryl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)valine
Nisis
Nisis||
Novartis brand of valsartan
Provas
S1894_Selleck
SAM001246581
SMR000466318
SPBio_001260
SPECTRUM1505209
Sanol brand of valsartan
Schwarz brand of valsartan
Spectrum2_001120
Spectrum3_001831
Spectrum4_000749
Spectrum5_001582
Spectrum_001796
TL8000869
Tareg
UNII-80M03YXJ7I
Vals
Valsarran
Valsartan (JAN/USAN/INN)
Valsartan [USAN:INN]
valsartan
walsartan
|Tareg
8Phosphodiesterase 3 InhibitorsPhase 4131
9Fibrinolytic AgentsPhase 42317
10Cyclooxygenase InhibitorsPhase 42778
11Bronchodilator AgentsPhase 42856
12Neuroprotective AgentsPhase 41672
13AnalgesicsPhase 411287
14diureticsPhase 41372
15Natriuretic AgentsPhase 41645
16Sodium Chloride Symporter InhibitorsPhase 4446
17Antihypertensive AgentsPhase 44095
18Vasodilator AgentsPhase 4, Phase 23438
19Protective AgentsPhase 47190
20Respiratory System AgentsPhase 44818
21Autonomic AgentsPhase 49774
22Phosphodiesterase InhibitorsPhase 41254
23Anesthetics, InhalationPhase 4649
24Anesthetics, IntravenousPhase 42406
25Central Nervous System DepressantsPhase 412806
26Anesthetics, GeneralPhase 42787
27Analgesics, OpioidPhase 43091
28AnestheticsPhase 4, Phase 1, Phase 29001
29Antirheumatic AgentsPhase 410627
30NarcoticsPhase 43486
31Hypnotics and SedativesPhase 42485
32Anti-Inflammatory Agents, Non-SteroidalPhase 44295
33AntipyreticsPhase 41534
34Anti-Asthmatic AgentsPhase 43369
35Anti-Inflammatory AgentsPhase 410355
36Analgesics, Non-NarcoticPhase 46260
37Peripheral Nervous System AgentsPhase 422776
38Platelet Aggregation InhibitorsPhase 4, Phase 22419
39Angiotensin Receptor AntagonistsPhase 41173
40Angiotensin-Converting Enzyme InhibitorsPhase 4711
41Angiotensin II Type 1 Receptor BlockersPhase 41078
42AngiotensinogenPhase 41161
43Hypolipidemic AgentsPhase 42721
44Anticholesteremic AgentsPhase 41983
45AntimetabolitesPhase 411774
46AntioxidantsPhase 42928
47
Angiotensin IIPhase 4116268521-88-0, 11128-99-7172198, 65143
Synonyms:
1-8-Angiotensin I
1-L-Aspasaginyl-5-L-valyl angiotensin octapeptide
Ang II
Angiotensin 2
Angiotensin II (human)
 
Angiotensin II (mouse)
Angiotonin
Asp-arg-val-TYR-ile-his-pro-phe
Human angiotensin II
Hypertensin
Ile(5)-angiotensin II
48Lipid Regulating AgentsPhase 42702
49
Alprostadilapproved, investigationalPhase 269745-65-3149351
Synonyms:
(11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-enoic acid
(11alpha,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid
(11alpha,13e,15S)-11,15-Dihydroxy-9-oxoprost-13-en-1-oic acid
(13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate
(13E,15S)-11alpha,15-dihydroxy-9-oxoprost-13-en-1-oic acid
(13e)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate
119314-69-1
11alpha,15alpha-Dihydroxy-9-oxo-13-trans-prostenoic acid
7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoic acid
745-65-3
82474_FLUKA
A0593_SIAL
AB00514004
AC-6095
AC1NQXHQ
Alista
Alprostadil
Alprostadil (JP15/USP/INN)
Alprostadil Alfadex
Alprostadil Prostoglandin E1
Alprostadilum
Alprox-TD
BIDD:GT0747
BML1-F06
BPBio1_001293
BRD-K52459643-001-06-0
BSPBio_001175
BSPBio_001488
Befar
Befar (TN)
C04741
CHEBI:15544
CHEMBL495
CID5280723
CPD000112594
Caverject
D00180
DB00770
Edex
FemLife
Femprox
HEI-507
HMS1361K10
HMS1571K17
HMS1791K10
HMS1989K10
HMS2052L11
 
HMS2090L08
IDI1_033958
LMFA03010134
MLS000758964
MLS001424250
MR 256
MR-256
MolPort-003-939-183
Muse
NCGC00025234-02
NCGC00025234-03
NCGC00025234-04
NCGC00025234-05
P5515_SIAL
P5515_SIGMA
P7527_SIGMA
P8908_SIGMA
PGE-1
PGE1
PGE1 Oligomer
PGE1 α-CD
PGE₁
Prestwick2_001018
Prestwick3_001018
Prink
Prink (TN)
Prost-13-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (11alpha,13E,15S)-, homopolymer
Prostaglandin E1
Prostaglandin e1
Prostavasin
Prostin VR
Prostin VR Pediatric
Prostin VR pediatric (TN)
Prostin vr
RayVa
SAM001246840
SAM001246845
SAM001247093
SMP2_000271
SMR000112594
ST50826271
Sugiran
Topiglan
U-10136
Viridal
Vitaros
alprostadil
l-Prostaglandin E1
50AnticoagulantsPhase 22516

Interventional clinical trials:

(show all 17)
idNameStatusNCT IDPhase
1Effects of Anesthetics on Postoperative Cognitive Function of Patients Undergoing Endovascular Repair of Aortic Aneurysm and Endovascular Treatment of Arteriosclerosis Obliterans of Lower Extremities.Unknown statusNCT02107170Phase 4
2Sufficient Treatment of Peripheral Intervention by CilostazolUnknown statusNCT00912756Phase 4
3Diuretics In the Management of Essential Hypertension (DIME) StudyUnknown statusNCT00131846Phase 4
4Study of Cilostazol and Probucol to Assess Their Effects on Atherosclerosis Related BiomarkerCompletedNCT00823849Phase 4
5Add-on Effects of Valsartan on Morbi- Mortality (KYOTO HEART Study)CompletedNCT00149227Phase 4
6TACT-NAGOYA: Therapeutic Angiogenesis Using Cell TransplantationUnknown statusNCT00145262Phase 2
7Safety and Efficacy Study of Autologous BM-MNC Processed by Two Methods for Treating Patients With Chronic Limb IschemiaUnknown statusNCT01446055Phase 1, Phase 2
8Autologous Bone Marrow For Lower Extremity Ischemia TreatingCompletedNCT00753025Phase 2
9Effectiveness and Safety of Adipose-Derived Regenerative Cells for the Treatment of Critical Lower Limb IschemiaEnrolling by invitationNCT02864654Phase 1, Phase 2
10A Safety/Efficacy Study of Alprostadil Liposomes for Injection to Treat Lower Extremity Arteriosclerosis ObliteransNot yet recruitingNCT02877173Phase 2
11Study to Assess the Efficacy and Safety of CLBS12 in Patients With Critical Limb Ischemia (CLI)Not yet recruitingNCT02501018Phase 2
12Preoperative Heart Rate Variability and Baroreflex Sensitivity in ASO Patients During Various Sleep StagesCompletedNCT00712946
13HELP-Apheresis in Diabetic Ischemic Foot Treatment (H.A.D.I.F)CompletedNCT01518205
14ADDICTAO: Psychological and Addictive Profile of Patients With Buerger's DiseaseCompletedNCT01064206
15Long Superficial Femoral Artery Stenting With SuperA Interwoven Nitinol StentsRecruitingNCT03020290
16Purified CD34+ Cells Versus Peripheral Blood Mononuclear Cells in Treatment of Critical Limb IschemiaRecruitingNCT02089828
17Arterial Calcification in the DiabetesActive, not recruitingNCT02431234

Search NIH Clinical Center for Arteriosclerosis Obliterans

Inferred drug relations via UMLS67/NDF-RT45:


Cochrane evidence based reviews: arteriosclerosis obliterans

Genetic Tests for Arteriosclerosis Obliterans

About this section

Anatomical Context for Arteriosclerosis Obliterans

About this section

MalaCards organs/tissues related to Arteriosclerosis Obliterans:

35
Heart, Bone, Bone marrow, Skin, Smooth muscle, Endothelial, T cells

Animal Models for Arteriosclerosis Obliterans or affiliated genes

About this section

MGI Mouse Phenotypes related to Arteriosclerosis Obliterans:

40
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053858.0ADIPOQ, HGF, ICAM1, IL6, ITGA4, SELP
2MP:00053848.0ADIPOQ, HGF, ICAM1, IL6, ITGA4, SELP
3MP:00053977.2ADIPOQ, HGF, ICAM1, IL6, ITGA4, SELP

Publications for Arteriosclerosis Obliterans

About this section

Articles related to Arteriosclerosis Obliterans:

(show top 50)    (show all 241)
idTitleAuthorsYear
1
Beraprost Sodium Protects Against Diabetic Nephropathy in Patients with Arteriosclerosis Obliterans: A Prospective, Randomized, Open-label Study. (25959199)
2015
2
Retrograde perfusion of the hind leg in diabetic patients suffering from arteriosclerosis obliterans: theoretical considerations of oxygen supply and lymphatic flow based on rat models. (22259111)
2012
3
Study design of SEASON registry: prospective Surveillance of cardiovascular Events in an Antiplatelet-treated arterioSclerosis Obliterans patients in JapaN )SEASON). (20966606)
2010
4
Long-term follow-up of Symphony nitinol stents in iliac arteriosclerosis obliterans. (18270875)
2008
5
Close association of hypoadiponectinemia with arteriosclerosis obliterans and ischemic heart disease. (15877296)
2005
6
Low-density lipoprotein apheresis in a patient with arteriosclerosis obliterans and light chain deposition disease. (15224807)
2004
7
Clinical application of bone marrow implantation in patients with arteriosclerosis obliterans, and the association between efficacy and the number of implanted bone marrow cells. (15564705)
2004
8
Effects of low-density lipoprotein apheresis on plasma matrix metalloproteinase-9 and serum tissue inhibitor of metalloproteinase-1 levels in diabetic hemodialysis patients with arteriosclerosis obliterans. (12918586)
2003
9
Effect of low-density lipoprotein apheresis on plasma endothelin-1 levels in diabetic hemodialysis patients with arteriosclerosis obliterans. (14583180)
2003
10
Effects of sarpogrelate hydrochloride on adenosine diphosphate- or collagen-induced platelet responses in arteriosclerosis obliterans. (11505083)
2001
11
Platelet-derived microparticles in patients with arteriosclerosis obliterans: enhancement of high shear-induced microparticle generation by cytokines. (10822072)
2000
12
Heparin and exercise treatment in a patient with arteriosclerosis obliterans. (9276778)
1997
13
A rare case of arteriosclerosis obliterans without prominent risk factors complicated by idiopathic thrombocytopenic purpura. A case report. (8619516)
1996
14
Improved skin blood flow and cutaneous temperature in the foot of a patient with arteriosclerosis obliterans by vasopressin V1 antagonist (OPC21268). A case report. (7486224)
1995
15
Removal of LDL from plasma by adsorption reduces adhesion molecules on mononuclear cells in patients with arteriosclerosis obliterans. (7488336)
1995
16
Comparison of arteriosclerosis obliterans of lower limbs between China and Japan. (2225282)
1990
17
Systolic hypertension in patients with arteriosclerosis obliterans of the lower limbs. (3578917)
1987
18
Dipyridamole and aspirin in arteriosclerosis obliterans of the lower limbs. (3159212)
1985
19
Prevalence of severe arteriosclerosis obliterans in patients with diabetes mellitus. Relation to smoking and form of therapy. (7052035)
1982
20
Lack of effect of ischemia and dipyridamole on prostacyclin production in arteriosclerosis obliterans. (7041195)
1981
21
Severe ischemia of the lower extremity due to arteriosclerosis obliterans. (6153025)
1981
22
Successful therapy of advanced arteriosclerosis obliterans with prostacyclin. (86835)
1979
23
Serum lipids and lipoproteins in arteriosclerosis obliterans of the lower extremities. (750857)
1978
24
Survival after arterial reconstruction in arteriosclerosis obliterans of the lower limbs. Follow-up after 10-20 years. (654831)
1978
25
Factors influenced on prognosis of reconstructive surgery for peripheral arterial occlusion: comparative study between arteriosclerosis obliterans and thromboangiitis obliterans. (599159)
1977
26
Lumbar sympathectomy in arteriosclerosis obliterans: a clinical and ultrasound study. (604464)
1977
27
Arteriosclerosis obliterans. (1049003)
1976
28
Arteriosclerosis obliterans of the lower extremities in non-diabetic men: survival and causes of death. (1139967)
1975
29
Saphenous vein bypass grafts for arteriosclerosis obliterans in the femoropopliteal region. (4695292)
1973
30
Cigarette smoking and arteriosclerosis obliterans: an epidemiologic approach. (5007359)
1972
31
Arteriosclerosis obliterans in the lower extremities: correlation of clinical and angiographic findings. (5119840)
1971
32
The natural course of peripheral arteriosclerosis obliterans evaluated by flow measurements. (5802451)
1969
33
THROMBOANGIITIS OBLITERANS AND ARTERIOSCLEROSIS OBLITERANS. CLINICAL AND PROGNOSTIC DIFFERENCES. (14065946)
1963
34
A CLINICAL EVALUATION OF DIETHANOLAMINE SALT OF P-TOLYLMETHYLCARBINOL CAMPHORIC ACID (GALLOGEN) IN ARTERIOSCLEROSIS OBLITERANS. (14047141)
1963
35
Severe ischemia of lower extremity due to arteriosclerosis obliterans. (13955713)
1963
36
A follow-up study of arterial reconstructive procedures in arteriosclerosis obliterans. (13735232)
1961
37
The management of the patient with arteriosclerosis obliterans. (13736768)
1961
38
Treatment of diabetic ulcer with concomitant arteriosclerosis obliterans. (14424139)
1960
39
Iliofemoropopliteal arterial reconstructions for arteriosclerosis obliterans; factors influencing late patency. (13622959)
1959
40
Oxygen utilization and lactic acid formation in the legs at rest and during exercise in normal subjects and in patients with arteriosclerosis obliterans. (13660772)
1959
41
Arteriosclerosis obliterans. (13640435)
1959
42
Muscle blood flow in patients with arteriosclerosis obliterans. (13559561)
1958
43
Coronary (ischaemic) heart disease in patients with arteriosclerosis obliterans. (13394194)
1956
44
The use of hexamethonium in treatment of arteriosclerosis obliterans. (14364735)
1955
45
Arteriosclerosis obliterans; its diagnosis and treatment. (13096386)
1953
46
CLINICAL pathologic conference: diabetes mellitus with complications, including generalized arteriosclerosis, cerebral arteriosclerosis, coronary arteriosclerosis, hypertensive cardiovascular disease and arteriosclerosis obliterans of the extremities. (13011459)
1952
47
Arteriosclerosis obliterans as a cause of ulcer of the leg. (15398743)
1950
48
Management of arteriosclerosis obliterans in cold climates. (14774636)
1950
49
Sympathectomy for arteriosclerosis obliterans; rationale and results. (18934297)
1948
50
Arteriosclerosis obliterans of the abdominal aorta. (20999992)
1946

Variations for Arteriosclerosis Obliterans

About this section

Expression for genes affiliated with Arteriosclerosis Obliterans

About this section
Search GEO for disease gene expression data for Arteriosclerosis Obliterans.

Pathways for genes affiliated with Arteriosclerosis Obliterans

About this section

GO Terms for genes affiliated with Arteriosclerosis Obliterans

About this section

Cellular components related to Arteriosclerosis Obliterans according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1external side of plasma membraneGO:00098979.1ICAM1, IL6, SELP, VCAM1
2cell surfaceGO:00099868.2ADIPOQ, ICAM1, ITGA4, VCAM1
3extracellular spaceGO:00056158.0ADIPOQ, HGF, ICAM1, IL6, SELP, VCAM1

Biological processes related to Arteriosclerosis Obliterans according to GeneCards Suite gene sharing:

(show all 33)
idNameGO IDScoreTop Affiliating Genes
1membrane to membrane dockingGO:002261410.4ICAM1, VCAM1
2cellular response to nutrient levelsGO:003166910.3ICAM1, IL6
3negative regulation of hormone secretionGO:004688810.3ADIPOQ, IL6
4negative regulation of gluconeogenesisGO:004572110.2ADIPOQ, IL6
5response to amino acidGO:004320010.2ICAM1, IL6
6calcium-mediated signaling using intracellular calcium sourceGO:003558410.2SELP, VCAM1
7acute inflammatory responseGO:000252610.1IL6, VCAM1
8positive regulation of vasoconstrictionGO:004590710.1HTR2A, ICAM1
9cellular response to hepatocyte growth factor stimulusGO:003572910.1HGF, IL6
10negative regulation of extrinsic apoptotic signaling pathway via death domain receptorsGO:190204210.1HGF, ICAM1
11positive regulation of cell adhesionGO:004578510.0SELP, TPM1
12positive regulation of nitric oxide biosynthetic processGO:004542910.0ICAM1, IL6
13negative regulation of fat cell differentiationGO:004559910.0ADIPOQ, IL6
14positive regulation of leukocyte migrationGO:000268710.0ITGA4, SELP
15cell chemotaxisGO:00603269.9HGF, VCAM1
16heterophilic cell-cell adhesion via plasma membrane cell adhesion moleculesGO:00071579.9ICAM1, SELP, VCAM1
17defense response to Gram-negative bacteriumGO:00508299.9IL6, SELP
18response to organic cyclic compoundGO:00140709.7ICAM1, IL6, SELP
19cellular response to tumor necrosis factorGO:00713569.7ICAM1, IL6, VCAM1
20leukocyte tethering or rollingGO:00509019.7ITGA4, SELP, VCAM1
21agingGO:00075689.4HTR2A, IL6, VCAM1
22regulation of immune responseGO:00507769.4ICAM1, ITGA4, VCAM1
23response to lipopolysaccharideGO:00324969.4ICAM1, IL6, SELP, VCAM1
24regulation of cell shapeGO:00083609.4ICAM1, IL6, TPM1
25response to hypoxiaGO:00016669.3ADIPOQ, ICAM1, VCAM1
26response to ethanolGO:00454719.3ADIPOQ, ICAM1, VCAM1
27cellular response to cytokine stimulusGO:00713459.3IL6, ITGA4
28leukocyte migrationGO:00509009.3ICAM1, ITGA4, SELP
29extracellular matrix organizationGO:00301989.2ICAM1, ITGA4, VCAM1
30leukocyte cell-cell adhesionGO:00071599.2ICAM1, ITGA4, SELP, VCAM1
31positive regulation of ERK1 and ERK2 cascadeGO:00703749.0HTR2A, ICAM1, IL6
32positive regulation of peptidyl-tyrosine phosphorylationGO:00507318.6ADIPOQ, HGF, HTR2A, ICAM1, IL6
33response to drugGO:00424938.4ADIPOQ, HTR2A, ICAM1, IL6

Molecular functions related to Arteriosclerosis Obliterans according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1sialic acid bindingGO:00336919.7ADIPOQ, SELP

Sources for Arteriosclerosis Obliterans

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
26GTR
27HGMD
28HMDB
29ICD10
30ICD10 via Orphanet
31ICD9CM
32IUPHAR
33KEGG
36MedGen
38MeSH
39MESH via Orphanet
40MGI
43NCI
44NCIt
45NDF-RT
48NINDS
49Novoseek
51OMIM
52OMIM via Orphanet
56PubMed
57QIAGEN
62SNOMED-CT via Orphanet
66Tumor Gene Family of Databases
67UMLS
68UMLS via Orphanet